Goldman Sachs Group Inc Atreca, Inc. Transaction History

Goldman Sachs Group Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.13 - $0.38 $3,162 - $9,243	-24,324 Reduced 34.67%	45,831 $5,000
Q3 2023 May 14, 2024	BUY	$0.26 - $1.12 $6,324 - $27,242	24,324 Added 53.07%	70,155 $18,000
Q3 2023 Nov 14, 2023	SELL	$0.26 - $1.12 $1,455 - $6,268	-5,597 Reduced 7.39%	70,155 $18,000
Q2 2023 May 14, 2024	BUY	$0.88 - $1.22 $163 - $226	186 Added 0.25%	75,752 $74,000
Q2 2023 Aug 14, 2023	BUY	$0.88 - $1.22 $163 - $226	186 Added 0.25%	75,752 $74,000
Q1 2023 May 14, 2024	BUY	$0.91 - $1.82 $31,864 - $63,729	35,016 Added 86.35%	75,566 $86,000
Q1 2023 May 11, 2023	BUY	$0.91 - $1.82 $31,864 - $63,729	35,016 Added 86.35%	75,566 $86,000
Q4 2022 May 14, 2024	SELL	$0.78 - $1.68 $14,916 - $32,128	-19,124 Reduced 32.05%	40,550 $32,000
Q4 2022 Feb 13, 2023	SELL	$0.78 - $1.68 $14,916 - $32,128	-19,124 Reduced 32.05%	40,550 $32,000
Q3 2022 May 14, 2024	SELL	$1.59 - $2.74 $42,169 - $72,670	-26,522 Reduced 30.77%	59,674 $94,000
Q3 2022 Nov 10, 2022	SELL	$1.59 - $2.74 $42,169 - $72,670	-26,522 Reduced 30.77%	59,674 $0
Q2 2022 May 14, 2024	BUY	$1.56 - $3.25 $62,969 - $131,186	40,365 Added 88.07%	86,196 $154,000
Q2 2022 Aug 15, 2022	SELL	$1.56 - $3.25 $46,149 - $96,144	-29,583 Reduced 25.55%	86,196 $154,000
Q1 2022 May 16, 2022	SELL	$1.61 - $5.2 $116,124 - $375,060	-72,127 Reduced 38.38%	115,779 $367,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $340,714 - $746,723	118,716 Added 171.58%	187,906 $569,000
Q3 2021 Nov 10, 2021	BUY	$4.91 - $9.07 $339,722 - $627,553	69,190 New	69,190 $431,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.